Characteristics of Exceptional or Super Responders to Cancer Drugs

Mayo Clinic Proceedings

Volumn 90, Issue 12, 2015, Pages 1639-1649

  Prasad, Vinay ^a   Vandross, Andrae ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;

AGE; ARTICLE; CANCER CLASSIFICATION; CASE STUDY; CLINICAL FEATURE; DRUG RESPONSE; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; TRANSITIONAL CELL CARCINOMA; NEOPLASMS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 84953236641     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.08.017     Document Type: Article

References (51)

1. N. Takebe, L. McShane, and B. Conley Biomarkers: exceptional responders-discovering predictive biomarkers Nat Rev Clin Oncol 12 3 2015 132 134
2. A. Mullard Learning from exceptional drug responders Nat Rev Drug Discov 13 6 2014 401 402
3. A. Mullard NCI starts 'exceptional responder' hunt Nat Rev Drug Discov 13 11 2014 803
4. In search of exceptional responders Cancer Discov 5 1 2015 8
5. C. Sheridan Cancer centers zero in on exceptional responders Nat Biotechnol 32 8 2014 703 704 Erratum in Nat Biotechnol. 2014;32(11):1074. Dosage error in article text
6. V. Marx Cancer: a most exceptional response Nature 520 7547 2015 389 393
7. A.R. Brannon, and C.L. Sawyers "N of 1" case reports in the era of whole-genome sequencing J Clin Invest 123 11 2013 4568 4570
8. D.K. Chang, S.M. Grimmond, T.R. Evans, and A.V. Biankin Mining the genomes of exceptional responders Nat Rev Cancer 14 5 2014 291 292
9. Ledford H. Cancer researchers revisit 'failed' clinical trials. Nature news. http://www.nature.com/news/cancer-researchers-revisit-failed-clinical-trials-1.12835. Accessed September 10, 2015.
10. N. Wagle, B.C. Grabiner, E.M. Van Allen, and et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer N Engl J Med 371 15 2014 1426 1433
11. Staff N. The Exceptional Responders Initiative: welcoming more cases. 2015. http://www.cancer.gov/news-events/nci-update/2015/exceptional-responders-initiative. Accessed April 18, 2015.
12. A.S. Thonnard, L. Bosquee, and J.L. Corhay Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies [in French] Rev Med Liege 66 3 2011 121 125
13. Y. Godbert, B. Henriques de Figueiredo, F. Bonichon, and et al. Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma J Clin Oncol 33 20 2015 e84 e87
14. A. Takalkar, S. Adams, and V. Subbiah Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone Exp Hematol Oncol 3 2014 23
15. A. Loaiza-Bonilla, E. Clayton, E. Furth, M. O'Hara, and J. Morrissette Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine Ecancermedicalscience 8 2014 479
16. V. Subbiah, R.E. Brown, J. Buryanek, and et al. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist Mol Cancer Ther 11 11 2012 2541 2546
17. M. Ilander, P. Koskenvesa, S. Hernesniemi, T. Lion, K. Porkka, and S. Mustjoki Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-alpha monotherapy Leuk Lymphoma 55 4 2014 934 937
18. V. Subbiah, A. Naing, R.E. Brown, and et al. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures PLoS One 6 4 2011 e18424
19. V. Subbiah, F. Meric-Bernstam, G.B. Mills, and et al. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent(R)) a VEGFR2/PDGFRbeta/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial J Hematol Oncol 7 2014 52
20. E.M. Van Allen, V.W. Lui, A.M. Egloff, and et al. Genomic correlate of exceptional erlotinib response in head and neck squamous cell carcinoma JAMA Oncol 1 2 2015 238 244
21. V. Subbiah, R.E. Brown, M.F. McGuire, and et al. A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma Oncotarget 5 1 2014 95 102
22. D.L. Bajor, X. Xu, D.A. Torigian, and et al. Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma Cancer Immunol Res 2 11 2014 1051 1058
23. A. Berrebi, E. Feldberg, I. Spivak, and L. Shvidel Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly Haematologica 92 2 2007 e15 e16
24. C.M. Lovly, N.T. McDonald, H. Chen, and et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer Nat Med 20 9 2014 1027 1034
25. K. Hashimoto, H. Horinouchi, T. Ohtsuka, and et al. Salvage surgery for a super-responder by gefitinib therapy for advanced lung cancer Gen Thorac Cardiovasc Surg 60 12 2012 851 854
26. A.I. Daud, S.S. Krishnamurthi, M.N. Saleh, and et al. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors Clin Cancer Res 18 4 2012 1092 1100
27. U. Banerji, L. van Doorn, D. Papadatos-Pastos, and et al. A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors Clin Cancer Res 18 9 2012 2687 2694
28. A.J. Wagner, I. Malinowska-Kolodziej, J.A. Morgan, and et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors J Clin Oncol 28 5 2010 835 840
29. M. Zhang, A. Mahta, R.Y. Kim, S. Akar, and S. Kesari Durable remission of leptomeningeal metastases from hormone-responsive prostate cancer Med Oncol 29 2 2012 806 808
30. M.H. Voss, A.A. Hakimi, C.G. Pham, and et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy Clin Cancer Res 20 7 2014 1955 1964
31. H. Al-Ahmadie, G. Iyer, M. Hohl, and et al. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy Cancer Discov 4 9 2014 1014 1021
32. V. Subbiah, S.N. Westin, K. Wang, and et al. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein J Hematol Oncol 7 2014 8
33. N. Palma, J.C. Morris, S.M. Ali, J.S. Ross, and S.K. Pal Exceptional response to pazopanib in a patient with urothelial carcinoma harboring FGFR3 activating mutation and amplification Eur Urol 68 1 2015 168 170
34. S.M. Ali, V.A. Miller, J.S. Ross, and S.K. Pal Exceptional response on addition of everolimus to taxane in urothelial carcinoma bearing an NF2 mutation Eur Urol 67 6 2015 1195 1196
35. N. Wagle, B.C. Grabiner, E.M. Van Allen, and et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib Cancer Discov 4 5 2014 546 553
36. G. Iyer, A.J. Hanrahan, M.I. Milowsky, and et al. Genome sequencing identifies a basis for everolimus sensitivity Science 338 6104 2012 221
37. S. Mailankody, and V. Prasad Five years of cancer drug approvals: innovation, efficacy, and costs JAMA Oncol 1 4 2015 539 540
38. J. Chen, J.D. Tward, D.C. Shrieve, and Y.J. Hitchcock Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002 Am J Clin Oncol 31 5 2008 460 464
39. National Cancer Institute. SEER cancer statistics review 1975-2012. seer.cancer.gov Web site. http://seer.cancer.gov/csr/1975-2012/results-merged/sect-22-pancreas.pdf. Accessed September 10, 2015.
40. Survival statistics for cancer of the pancreas. aboutcancer.com Web site. http://www.aboutcancer.com/pancreas3.htm. Accessed September 10, 2015.
41. V. Prasad, and S. Mailankody The accelerated approval of oncologic drugs: lessons from ponatinib JAMA 311 4 2014 353 354
42. M. Talpaz, K.B. McCredie, G.M. Mavligit, and J.U. Gutterman Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia Blood 62 3 1983 689 692
43. M. Talpaz, R. Hehlmann, A. Quintás-Cardama, J. Mercer, and J. Cortes Re-emergence of interferon-α in the treatment of chronic myeloid leukemia Leukemia 27 4 2013 803 812
44. D.V. Catenacci Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity Mol Oncol 9 5 2015 967 996
45. N. Mehra, D. Lorente, and J.S. de Bono What have we learned from exceptional tumour responses? Review and perspectives Curr Opin Oncol 27 3 2015 267 275
46. A.J. Redig, and P.A. Jänne Basket trials and the evolution of clinical trial design in an era of genomic medicine J Clin Oncol 33 9 2015 975 977
47. C. Willyard 'Basket studies' will hold intricate data for cancer drug approvals Nat Med 19 6 2013 655
48. S.J. Ruberg, L. Chen, and Y. Wang The mean does not mean as much anymore: finding subgroups for tailored therapeutics Clin Trials 7 5 2010 574 583
49. V. Prasad, C. Kim, M. Burotto, and A. Vandross The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses JAMA Intern Med 175 8 2015 1389 1398
50. R.S. Herbst, D.R. Gandara, F.R. Hirsch, and et al. Lung Master Protocol (Lung-MAP) - a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400 Clin Cancer Res 21 7 2015 1514 1524
51. P. Doshi, S.N. Goodman, and J.P. Ioannidis Raw data from clinical trials: within reach? Trends Pharmacol Sci 34 12 2013 645 647